We are live on
!
Find out more
PCM
Penserra Capital Management Portfolio holdings
AUM
$8.52B
1-Year Est. Return
37.76%
This Fund
S&P 500
This Quarter
Est. Return
+7.88%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$5.51B
AUM Growth
+$99.7M
(+1.8%)
Cap. Flow
-$170M
Cap. Flow
% of AUM
-3.09%
Top 10 Holdings %
Top 10 Hldgs %
18.48%
Holding
1,445
New
336
Increased
635
Reduced
341
Closed
112
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$53.9M |
| 2 |
Pinduoduo
PDD
|
+$47.7M |
| 3 |
LOGC
ContextLogic
LOGC
|
+$25.5M |
| 4 |
ThredUp
TDUP
|
+$25.1M |
| 5 |
Upwork
UPWK
|
+$24.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolve Group
RVLV
|
+$66M |
| 2 |
NetEase
NTES
|
+$50.7M |
| 3 |
TripAdvisor
TRIP
|
+$46.2M |
| 4 |
Groupon
GRPN
|
+$44.5M |
| 5 |
QVCGA
QVC Group Inc Series A
QVCGA
|
+$43.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 30% |
| 2 | Technology | 24.74% |
| 3 | Communication Services | 13.13% |
| 4 | Financials | 5.61% |
| 5 | Industrials | 4.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Keros Therapeutics
KROS
$221M
| $22K | ﹤0.01% |
530
+10
| +2% | +$542 |
|
1127
Morgan Stanley
MS
$340B
| $22K | ﹤0.01% |
+250
| New | +$21.4K |
|
1128
Rhythm Pharmaceuticals
RYTM
$7.96B
| $22K | ﹤0.01% |
1,145
+35
| +3% | +$727 |
|
1129
Scholar Rock
SRRK
$6.44B
| $22K | ﹤0.01% |
785
+20
| +3% | +$612 |
|
1130
T. Rowe Price
TROW
$24.3B
| $22K | ﹤0.01% |
115
-6,590
| -98% | -$1.23M |
|
1131
Amphastar Pharmaceuticals
AMPH
$916M
| $21K | ﹤0.01% |
1,085
+15
| +1% | +$283 |
|
1132
AutoNation
AN
$6.92B
| $21K | ﹤0.01% |
224
+39
| +21% | +$3.82K |
|
1133
Boston Scientific
BSX
$71.5B
| $21K | ﹤0.01% |
+500
| New | +$21K |
|
1134
Innoviva
INVA
$1.48B
| $21K | ﹤0.01% |
1,580
-715
| -31% | -$8.95K |
|
1135
Iron Mountain
IRM
$36.1B
| $21K | ﹤0.01% |
505
-216
| -30% | -$9.06K |
|
|
MRSN
1136
DELISTED
Mersana Therapeutics
MRSN
| $21K | ﹤0.01% |
63
| – | – |
|
1137
Omeros
OMER
$959M
| $21K | ﹤0.01% |
1,420
+30
| +2% | +$504 |
|
|
RNAM
1138
DELISTED
Avidity Biosciences
RNAM
| $21K | ﹤0.01% |
855
+10
| +1% | +$233 |
|
1139
Theravance Biopharma
TBPH
$877M
| $21K | ﹤0.01% |
1,485
+25
| +2% | +$469 |
|
|
GTHX
1140
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $21K | ﹤0.01% |
960
+15
| +2% | +$333 |
|
|
CCXI
1141
DELISTED
ChemoCentryx, Inc.
CCXI
| $21K | ﹤0.01% |
1,590
+25
| +2% | +$616 |
|
|
ZGNX
1142
DELISTED
Zogenix, Inc.
ZGNX
| $21K | ﹤0.01% |
1,270
+15
| +1% | +$276 |
|
1143
Arcturus Therapeutics
ARCT
$211M
| $20K | ﹤0.01% |
600
+20
| +3% | +$677 |
|
1144
American States Water
AWR
$3.46B
| $20K | ﹤0.01% |
256
+171
| +201% | +$13.6K |
|
1145
Energizer
ENR
$1.55B
| $20K | ﹤0.01% |
472
+307
| +186% | +$14.4K |
|
1146
Enanta Pharmaceuticals
ENTA
$400M
| $20K | ﹤0.01% |
460
| – | – |
|
|
ITOS
1147
DELISTED
iTeos Therapeutics
ITOS
| $20K | ﹤0.01% |
800
+10
| +1% | +$238 |
|
|
JKS
1148
JinkoSolar
JKS
$891M
| $20K | ﹤0.01% |
+360
| New | +$13.7K |
|
1149
Labcorp
LH
$25.9B
| $20K | ﹤0.01% |
+87
| New | +$19.8K |
|
1150
Li Auto
LI
$12.7B
| $20K | ﹤0.01% |
+592
| New | +$13.9K |
|
Similar funds
GRQ
IC
NB
DM
ACM
FT
NW
AAF
Penserra Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Penserra Capital Management held 1,445 positions worth $5.51B, up 1.8% from $5.41B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Penserra Capital Management withdrew a net $170M in Q2 2021, closing 112 positions and reducing 341 holdings. Its most notable exit was Just Eat Takeaway.com N.V. American Depositary Shares, an estimated $23.3M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 30% of assets, down from 33% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Penserra Capital Management opened a new position in ContextLogic worth $28.5M.
- Penserra Capital Management's largest Q2 2021 buy was ContextLogic: 72,047 shares worth $28.5M.
- Penserra Capital Management added most to Advanced Micro Devices in Q2 2021, an estimated $53.9M increase.
- Penserra Capital Management's biggest Q2 2021 reduction was Revolve Group, cutting an estimated $66M.
- Penserra Capital Management fully exited Just Eat Takeaway.com N.V. American Depositary Shares in Q2 2021, selling an estimated $23.3M.
- Penserra Capital Management's ten largest holdings make up 18% of its $5.51B portfolio in Q2 2021.
- Penserra Capital Management opened 336 new positions and closed 112 in Q2 2021.
- Penserra Capital Management's portfolio value rose 1.8% quarter-over-quarter to $5.51B.
Based on Penserra Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.